Kurser indlæses...
Prognose
Analytikernes gennemsnitlige kursmål er 45,06 € (-3,92 %). Medianen er 38,29 € (-18,36 %).
| Køb |
14 |
| Behold |
3 |
| Sælg |
1 |
Nyheder Til nyhedsfeedet
Orbis manager targets "fat-tail" stocks such as Genmab, Glencore and Cinemark
Graeme Forster, head of Orbis’s international equity strategy, builds a concentrated portfolio of undervalued companies that offer asymmetric upside—stocks with a positive-skew probability of a large payoff. Positions include Genmab for antibody-platform drug optionality, Glencore and other miners as inflation/commodity hedges, SK Hynix via discounted holding-company structures, and movie-theater operators on a theatrical-revival thesis. Orbis charges incentive fees tied to outperformance and emphasizes buying present earnings while capturing optional future upside rather than paying for narratives-driven growth stocks. » Mere på forbes.com
Genmab: Epcoritamab improves progression-free survival in phase-3 study
The phase-3 EPCORE DLBCL-1 trial showed that Epcoritamab monotherapy improved progression-free survival with a hazard ratio of 0.74 (95% CI 0.60–0.92) versus standard therapies in 483 patients with relapsed/refractory DLBCL. Overall response rate, duration of response and time to next treatment also improved, while overall survival showed no significant benefit (HR 0.96). Genmab and partner AbbVie plan to discuss the results with regulatory authorities; Epcoritamab is already approved in more than 65 countries for certain lymphoma indications. The company reports a strong balance sheet and a high gross margin (94.4%); the stock rose significantly in the prior year and Genmab plans further analyses and additional phase-3 data in 2026. » Mere på de.investing.com
Genmab finances Merus takeover with $2.5bn bonds
Genmab plans to issue $2.5bn of senior notes to fund the takeover of Merus: $1.5bn senior secured (due 2032) and $1bn unsecured (due 2033). It has also launched syndication of a $2bn senior secured term‑loan B facility; together with an already syndicated $1bn term‑loan A facility and a $500m revolving credit line, the proceeds are intended to cover the acquisition and related costs. The notes will initially be secured by issuance proceeds held in segregated accounts and later guaranteed by certain assets; they include market‑standard covenants and are targeted at institutional investors outside the US. Genmab currently reports more cash than debt and a very low leverage ratio; the company also posted strong Q3 growth (YTD revenue +21%, operating profit +52%), while the stock slipped slightly in premarket trading and Truist marginally lowered its price target. » Mere på de.investing.com
Virksomhedstal
| (EUR) | juni 2026 | YoY |
|---|---|---|
| Omsætning | 1,01 mia. | 28,98 % |
| Bruttofortjeneste | 938,42 mio. | 27,46 % |
| Nettoresultat | 265,49 mio. | 6,85 % |
| EBITDA | 377,65 mio. | 0,62 % |
Fundamentale data
| Nøgletal | Værdi |
|---|---|
Markedsværdi | 30,18 mia. € |
Antal aktier | 614,9 mio. |
Højeste/laveste i 52 uger | 53,40 € - 21,03 € |
| Udbytte | Nej |
Beta | 0,65 |
P/E (PE Ratio) | 42,00 |
PEG (PEG Ratio) | -0,49 |
K/I (PB Ratio) | 5,53 |
P/S (PS Ratio) | 3,43 |
Virksomhedsprofil
Genmab A/S udvikler antistofbehandlinger til behandling af kræft og andre sygdomme, primært i Danmark. Virksomheden markedsfører DARZALEX, et humant monoklonalt antistof til behandling af patienter med multipelt myelom (MM); teprotumumab til behandling af skjoldbruskkirtelrelateret øjensygdom; ofatumurnab, et humant monoklonalt antistof til behandling af kronisk lymfatisk leukæmi (CLL) og multipel sclerose; og amivantamab til avanceret eller metastatisk mave- eller spiserørskræft samt NSCLC. Dens produkter omfatter daratumumab til behandling af MM, ikke-MM blodkræft og AL-amyloidose; GEN1047; tisotumab vedotin til behandling af livmoderhalskræft, æggestokkræft og solide kræftformer; DuoBody-PD-L1x4-1BB og DuoBody-CD40x4-1BB til behandling af solide tumorer; epcoritamab til recidiverende/refraktær diffus storcellet B-cellelymfom og kronisk lymfatisk leukæmi; og HexaBody-CD38 og DuoHexaBody-CD37 til behandling af hæmatologiske maligniteter. Virksomheden udvikler desuden produkter, som er i fase 2, herunder teclistamab til vaso-occlusive kriser; camidanlumab tesirin til behandling af Hodgkin-lymfom og solide tumorer; JNJ-64007957 og JNJ-64407564 til behandling af MM; PRV-015 til behandling af cøliaki; Mim8 til behandling af hæmofili A; og Lu AF82422 til behandling af multisystematrofi. Derudover har den cirka 20 aktive prækliniske programmer. Virksomheden har en kommerciel licens- og samarbejdsaftale med Seagen Inc. om fælles udvikling af tisotumab vedotin. Den har også en samarbejdsaftale med CureVac AG om forskning og udvikling af differentierede mRNA-baserede antistofprodukter; med AbbVie om udvikling af epcoritamab; og samarbejder med BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS og Bolt Biotherapeutics, Inc. Genmab A/S blev grundlagt i 1999 og har hovedsæde i København, Danmark.
| Navn | Genmab ADR |
| CEO | Jan van de Winkel |
| Hjemsted | Copenhagen,
cd USA |
| Websted | |
| Sektor | Materialer |
| Branche | Kemikalier |
| Børsnotering | 01.06.2009 |
| Medarbejdere | 3.119 |
Deep Dive
Tickersymboler
| Børs | Symbol |
|---|---|
NASDAQ | GMAB |
Frankfurt | GE91.F |
Düsseldorf | GE91.DU |
München | GE91.MU |
